Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

June 18, 2007

Analysis of:FDA Advisory Committee Did Not Recommend Approval of Rimonabant (ZIMULTI(R)) for Use in Obese and Overweight Patients With Associated Risks Factors | www.pipelinereview.com

This is a severe blow for the company which is now forced to consider external growth, but is not expert in out-of-France acquisitions. Rimonabant was meant to become THE sanofi-aventis blockbuster for the next 5 years at least. Also, the R&D productivity at sanofi-aventis will be questioned, since so little information filtered out of the Company about the potential risks of rimonabant not being approved. For other centrally-acting product for peripheral conditions such as obesity/cardiometabolic disorders, FDA and EMEA will be even more severe and restrictive in the future.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS